Hello,
Welcome to
- More and more drug companies are pivoting to RNA;
- We have the pitch deck that clinical trials software startup Slope used to raise $20 million;
- Dermatologists are turning to social media and telehealth to fight misinformation.
If you're new to this newsletter, sign up here. Comments, tips? Email me at lrosenbaum@insider.com or tweet @leah_rosenbaum. Let's get to it...
Everyone from pharma giants to startup biotechs wants in on the hottest way to develop drugs
- Drug companies large and small are storming into
RNA research. - The industry's enthusiasm is driven by the stunning success of mRNA-based
coronavirus vaccines. - The RNA trend raises a classic biotech question: Is this a boom or a bubble?
This 10-slide presentation convinced top VC firm NEA to invest $20 million in its first clinical operations startup
- Slope makes software and lab kits for clinical trials. It raised $20 million in Series A funding.
- It is the Silicon Valley VC firm NEA's first investment in the booming clinical operations industry.
- Slope hopes to automate processes that are inefficient for researchers running clinical trials.
How dermatologists are turning to social media and telehealth to combat misinformation and stay competitive
- A Deloitte survey found that patients were increasingly willing to seek health advice online.
- Dermatologists are using social media to fight the misinformation people often find online.
- Some dermatologists are opting to keep offering online visits as things reopen.
More stories we're reading:
- New York's largest healthcare provider has fired 1,400 employees who refused to get COVID-19 vaccinations (Insider)
- See how much the government and taxpayers have paid to fund a new COVID antiviral pill (Axios)
- India will pay $670 to next of kin of COVID-19 victims in compensation for their loss (Insider)
- A quarter of companies now have COVID vaccine mandates (Bloomberg)
-Leah